

Prescription Drug Task Force

PBM OVERSIGHT SUBCOMMITTEE MEETING

List of Shared Documents

Monday, December 16, 2024

Please see below for a listing of documents and resources shared by participants in the 12/16/2024 meeting of the Prescription Drug Task Force Subcommittee on PBM Oversight.

Note that inclusion of any item on this list does not reflect the views of the Connecticut General Assembly, the chairs of this task force, or the task force membership. They are made available for the benefit of all members, to facilitate conversation, and for the sake of transparency.

- I. At 11:00AM Sam Hallemeier shared the following link as part of the ongoing conversation without additional comment: <https://facts.pcmanet.org/windfall/>.
- II. At 11:29AM Sam Hallemeier shared the following link, commenting "Here is the 2023 Rebate report which shows rebates are being passed back to plan sponsors:" <https://portal.ct.gov/cid/-/media/cid/reports/pbm-rebate-report/2023-pharmacy-benefit-manager-rebate-report.pdf?rev=230980e7096243d3a67f0bc3142f2931>
- III. At 11:42AM Patricia Blodgett shared the following link, commenting "Section 7 details the PBM study:" <https://www.cga.ct.gov/2023/act/Pa/pdf/2023PA-00171-R00HB-06669-PA.PDF>
- IV. Jim Carson shared the following resource via email: <https://portal.ct.gov/cid/-/media/cid/reports/pbm-rebate-report/2024-pharmacy-benefit-manager-rebate-report.pdf?rev=01838181d06846ed8b7b0ecc6c278218v>
- V. Christina Hatfield shared the following resources via email:
 - a. At least 1 in 10 medicines in low- and middle-income countries are substandard or falsified per the World Health Organization (<https://www.who.int/news-room/fact-sheets/detail/substandard-and-falsified-medical-products>). Pfizer has a good source on the counterfeit medication problem locally and globally (https://www.pfizer.com/news/articles/fake_drugs_101_facts_on_illegal_counterfeit_drugs). DSCSA was developed to as a first step help detect

counterfeit medications prior to reaching patients (see the attached Counsel of Strategic Risk's paper on the National Security Need to Optimize the Drug Supply Chain and Security Act). If the state determines to move forward with drug importation, it will be very important to work closely with various stakeholders to not undermine the initial steps taken to help ensure the integrity of the medications patients receive.

- b. US Federal Trade Commission's recent report (July 2024) on PBMs:
<https://www.ftc.gov/reports/pharmacy-benefit-managers-report>